Page 84 - Demo

Chapter 48219. Peters GJ, et al. (2013) Folate homeostasis of cancer cells affects sensitivity to not only antifolates but also other non-folate drugs: effect of MRP expression. Pteridines Volume 24 (1):81-86. doi:10.1515/pterid-2013-001920. Giaccone G, Gonzalez-Larriba JL, van Oosterom AT, Alfonso R, Smit EF, Martens M, Peters GJ, van der Vijgh WJ, Smith R, Averbuch S, Fandi A (2004) Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors. Ann Oncol 15 (5):831-83821. Savonije JH, Spanier BW, van Groeningen CJ, Giaccone G, Pinedo HM (2001) [Decline in the need for blood transfusions in cancer patients due to the use of epoietin alfa during cisplatin based chemotherapy]. Ned Tijdschr Geneeskd 145 (18):878-88122. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR, Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United K (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358 (1):36-46. doi:10.1056/NEJMoa07314923. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jager E, Arbeitsgemeinschaft Internistische O (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26 (9):1435-1442. doi:10.1200/JCO.2007.13.937824. van Meerten E, Eskens FA, van Gameren EC, Doorn L, van der Gaast A (2007) First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study. Br J Cancer 96 (9):1348-1352. doi:10.1038/sj.bjc.660375025. Mohammad NH, ter Veer E, Ngai L, Mali R, van Oijen MG, van Laarhoven HW (2015) Optimal firstline chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis. Cancer Metastasis Rev 34 (3):429-441. doi:10.1007/s10555-015-9576-y26. Morgan C, Tillett T, Braybrooke J, Ajithkumar T (2011) Management of uncommon chemotherapyinduced emergencies. Lancet Oncol 12 (8):806-814. doi:10.1016/S1470-2045(10)70208-427. Cassidy J, Misset JL (2002) Oxaliplatin-related side effects: characteristics and management. Semin Oncol 29 (5 Suppl 15):11-20. doi:10.1053/sonc.2002.3552428. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH (1993) Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 270 (22):2693-269829. Niyikiza C, Baker SD, Seitz DE, Walling JM, Nelson K, Rusthoven JJ, Stabler SP, Paoletti P, Calvert AH, Allen RH (2002) Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 1 (7):545-55230. Ciccolini J, Serdjebi C, Peters GJ, Giovannetti E (2016) Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. Cancer Chemother Pharmacol 78 (1):1-12. doi:10.1007/s00280-016-3003-031. Rizzuto I, Ghazaly E, Peters GJ (2017) Pharmacological factors affecting accumulation of gemcitabine%u2019s active metabolite, gemcitabine triphosphate. Pharmacogenomics 18 (9):911-925. doi:10.2217/pgs2017-003432. Bergman AM, Pinedo HM, Peters GJ (2002) Determinants of resistance to 2%u2019,2%u2019-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 5 (1):19-3333. Patterson RE, Neuhouser ML, Hedderson MM, Schwartz SM, Standish LJ, Bowen DJ (2003) Changes in diet, physical activity, and supplement use among adults diagnosed with cancer. J Am Diet Assoc 103 (3):323-328. doi:10.1053/jada.2003.5004534. Velicer CM, Ulrich CM (2008) Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review. J Clin Oncol 26 (4):665-673. doi:10.1200/JCO.2007.13.590535. Ernst E (2011) How Much of CAM Is Based on Research Evidence? Evid Based Complement Alternat Med 2011:676490. doi:10.1093/ecam/nep04436. Zhang L, Ma J, Han Y, Liu J, Zhou W, Hong L, Fan D (2016) Targeted therapy in esophageal cancer. Expert Rev Gastroenterol Hepatol 10 (5):595-604. doi:10.1586/17474124.2016.114003637. Shah MA (2015) Update on metastatic gastric and esophageal cancers. J Clin Oncol 33 (16):1760-1769. doi:10.1200/JCO.2014.60.1799